Latest filings (excl ownership)
6-K
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4
17 Apr 24
6-K
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million
10 Apr 24
6-K
BioLineRx Announces $6 Million Registered Direct Offering
1 Apr 24
424B5
Prospectus supplement for primary offering
1 Apr 24
20-F/A
2023 FY
Annual report (foreign) (amended)
26 Mar 24
20-F
2023 FY
Annual report (foreign)
26 Mar 24
6-K
BioLineRx Reports 2023 Financial Results and Recent Corporate
26 Mar 24
6-K
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent
4 Mar 24
6-K
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial
28 Feb 24
6-K
Current report (foreign)
16 Feb 24
EFFECT
Notice of effectiveness
8 Jan 24
S-8
Registration of securities for employees
29 Dec 23
F-3
Shelf registration (foreign)
29 Dec 23
6-K
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating
21 Dec 23
6-K
Current report (foreign)
12 Dec 23
6-K
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
20 Nov 23
6-K
BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide
12 Oct 23
6-K
BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination
28 Sep 23
6-K
BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple
11 Sep 23
6-K
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
30 Aug 23
6-K
Current report (foreign)
30 Aug 23
6-K
Current report (foreign)
8 Aug 23
6-K
BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic
17 Jul 23
6-K
Notice of Annual General Meeting of Shareholders
23 Jun 23
6-K
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
24 May 23
6-K
Current report (foreign)
25 Apr 23
6-K
BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating
17 Apr 23
20-F
2022 FY
Annual report (foreign)
22 Mar 23
6-K
BioLineRx Reports 2022 Financial Results and Recent Corporate
22 Mar 23
6-K
BioLineRx Announces Clinical Trial Collaboration with Washington University School of
6 Mar 23
S-8
Registration of securities for employees
20 Jan 23
6-K
BioLineRx Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer
4 Jan 23
6-K
BioLineRx Announces Results from Phase 1/2a Study of Investigational
20 Dec 22
6-K
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
15 Nov 22
6-K
Current report (foreign)
10 Nov 22
6-K
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
4 Nov 22
6-K
BioLineRx Announces Presentations on Cost-Effectiveness of Motixafortide in Multiple Myeloma
3 Nov 22
6-K
BioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization
27 Sep 22
6-K
Current report (foreign)
21 Sep 22
424B5
Prospectus supplement for primary offering
20 Sep 22
Latest ownership filings
SC 13D
Hong Seng Technology Ltd
26 Oct 23
SC 13G/A
INTRACOASTAL CAPITAL, LLC
11 Feb 22
SC 13G/A
NOVARTIS PHARMA AG
16 Feb 21
SC 13G/A
Altium Capital Management LP
12 Feb 21
SC 13G/A
Senvest Management, LLC
12 Feb 21
SC 13G/A
INTRACOASTAL CAPITAL, LLC
29 Jan 21
SC 13G/A
SABBY MANAGEMENT, LLC
6 Jan 21
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
3 Nov 20
SC 13G
ARMISTICE CAPITAL, LLC
5 Jun 20
SC 13G
INTRACOASTAL CAPITAL, LLC
5 Jun 20
SC 13G
Altium Capital Management LP
5 Jun 20
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
2 Jun 20
SC 13G
SABBY MANAGEMENT, LLC
26 May 20
SC 13G
Beneficial ownership report
14 Feb 20
SC 13G/A
Beneficial ownership report (amended)
7 Feb 20
SC 13D/A
BioLineRx Ltd.
1 Mar 19
SC 13G
BioLineRx Ltd.
8 Feb 19
SC 13G/A
BioLineRx Ltd.
8 Feb 19
SC 13G/A
BioLineRx Ltd.
12 Feb 18
SC 13G/A
BioLineRx Ltd.
14 Dec 17
SC 13D
BioLineRx Ltd.
8 Aug 17
SC 13G
BioLineRx Ltd.
10 Apr 17
SC 13D/A
BioLineRx Ltd.
8 Mar 17
SC 13G/A
BioLineRx Ltd.
13 Feb 17
SC 13G/A
BioLineRx Ltd.
13 Feb 17
SC 13G/A
BioLineRx Ltd.
16 Feb 16
SC 13G/A
BioLineRx Ltd.
12 Feb 16
SC 13G/A
BioLineRx Ltd.
12 Feb 16
SC 13D/A
BioLineRx Ltd.
16 Jun 15
SC 13G
BioLineRx Ltd.
16 Mar 15
SC 13G/A
BioLineRx Ltd.
17 Feb 15
SC 13G/A
BioLineRx Ltd.
9 Jan 15
SC 13G
BioLineRx Ltd.
7 Jan 15
SC 13G
BioLineRx Ltd.
22 Dec 14
SC 13G
BioLineRx Ltd.
14 Mar 14
SC 13D/A
BioLineRx Ltd.
10 Mar 14
SC 13G/A
BioLineRx Ltd.
13 Feb 14
SC 13D/A
FCMI FINANCIAL CORP ET AL
8 Mar 13
SC 13D/A
FCMI FINANCIAL CORP ET AL
16 Oct 12
SC 13D/A
FCMI FINANCIAL CORP ET AL
2 Apr 12